Conflict of interest: none declared.
Clinical dermatology ● Original article
Comparison of oral ivermectin vs. lindane lotion 1% for the treatment of scabies
Article first published online: 15 JUN 2013
© 2013 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 38, Issue 7, pages 719–723, October 2013
How to Cite
Mohebbipour, A., Saleh, P., Goldust, M., Amirnia, M., Zadeh, Y. J., Mohamad, R. M. and Rezaee, E. (2013), Comparison of oral ivermectin vs. lindane lotion 1% for the treatment of scabies. Clinical and Experimental Dermatology, 38: 719–723. doi: 10.1111/ced.12079
- Issue published online: 18 SEP 2013
- Article first published online: 15 JUN 2013
- Manuscript Accepted: 21 AUG 2012
Scabies is a common parasitic infestation that is an important public-health problem in many resource-poor regions. It is commonly treated with the insecticides ivermectin and permethrin.
To compare the efficacy and safety of oral ivermectin vs. lindane lotion 1% for the treatment of scabies.
In total, 148 patients with scabies were enrolled, and were randomized into two groups: the first group received a single dose of oral ivermectin 200 μg/kg body weight, and the second group were treated with two applications of topical lindane lotion 1%, with a 1-week interval between applications. Treatment was evaluated at intervals of 2 and 4 weeks, and if there was treatment failure at the 2-week follow-up, treatment was repeated.
A single dose of ivermectin provided a cure rate of 60.8% at the 2-week follow-up, which increased to 89.1% at the 4-week follow-up. after crossing over to the lindane lotion 1% group. Treatment with two applications of lindane lotion 1%, with a 1-week interval between them, was effective in 47.2% of patients at the 2-week follow-up, which increased to 72.9% at the 4-week follow-up after this treatment was repeated.
A single dose of ivermectin was as effective as two applications of lindane lotion 1% at the 2-week follow-up. After repeat treatment, ivermectin was superior to lindane lotion 1% at the 4-week follow up. The delay in clinical response with ivermectin suggests that it may not be effective against all the stages in the life cycle of the parasite.